(MCK) McKesson - Ratings and Ratios

McKesson Corporation is a healthcare services provider operating in the United States and internationally, leveraging its four business segments - U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International - to deliver a broad range of pharmaceuticals, medical supplies, and information technology solutions to various healthcare providers.

The companys diversified business model enables it to serve a wide customer base, including community-based oncology and specialty practices, pharmacies, hospitals, long-term care centers, and clinics. Through its U.S. Pharmaceutical segment, McKesson provides pharmaceutical distribution, practice management, and business solutions, while its RxTS segment offers medication access and affordability services, prescription decision support, and electronic prior authorization services to biopharma and life sciences partners.

McKessons Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and biomedical maintenance services to healthcare providers, and its International segment delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, and institutions. The companys long history, dating back to 1833, and its commitment to connecting patients with the medicines they need, position it as a significant player in the healthcare industry.

Analyzing the , we observe that the stocks current price is 719.51, slightly above its 20-day SMA of 708.85 and 50-day SMA of 693.60, indicating a positive short-term trend. The 200-day SMA of 600.50 suggests a strong long-term uptrend. With an ATR of 16.35 (2.27%), the stock has shown moderate volatility. Considering the , McKessons market capitalization stands at 89.1 billion USD, with a P/E ratio of 27.71 and a forward P/E of 19.12, indicating a relatively high valuation.

Based on the and , a forecast for McKesson Corporation can be made. Given the stocks current price and the support levels at 716.1, 641.9, and 627.0, a potential pullback to the 641.9 support level could be expected. However, considering the long-term uptrend and the companys strong market position, a rebound is likely. A potential target price could be around 750-760, representing a 4-5% increase from the current price. Investors should monitor the stocks performance relative to its SMA20, SMA50, and SMA200, as well as its ATR, to adjust their strategies accordingly.